Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, added, “WuXi Biologics’ increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company’s global strategy to work in close proximi...
Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, added, "WuXi Biologics' increased capacity inGermanyis intended to meet the growing needs of our global customers, especially those inEurope, thereby aligning us with the company's global strategy to work in close proxim...
AGC Biologics is a global contract development and manufacturing organization. AGC Biologics is the product of the convergence and integration of Asahi Glass Company Life Sciences, CMC Biologics, and BIOMEVA GmbH. Discover the right solution for your team ...
InJanuary 2020, the Group and Bayer jointly announced that WuXi Biologics Germany GmbH will acquire the operations of one of Bayer's final DP manufacturing plants in Leverkusen,Germany, and purchase the associated equipment, in combination with a long-term lease of the building. Based on a manuf...
In 2012, WuXi opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi city. That year WuXi also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 anti for rheumatoid arthritis for the Chinese...
Dr. Wu has concurrently been serving as a non-executive director of WuXi Biologics (Cayman) Inc. (stock code: 2269.HK). Dr. Wu obtained a bachelor's degree in molecular biology from University of Science and Technology of China (中國科學技術大學) in the PRC and a Ph.D. degree in ...